Zydus Lifesciences has gained the US Food and Drug Administration’s (FDA) approval to produce and market its Indomethacin suppositories. The drug is used to treat moderate to severe rheumatoid arthritis and acute flares of chronic disease, among other conditions. Zydus has been awarded 180-day CGT exclusivity to market the product after US authorities deemed there was a lack of competition.
